[go: up one dir, main page]

PE20251270A1 - COMPOUND ORAL FORMULATION COMPRISING EVOGLIPTIN AND METFORMIN, AND METHODS OF PREPARING SAME - Google Patents

COMPOUND ORAL FORMULATION COMPRISING EVOGLIPTIN AND METFORMIN, AND METHODS OF PREPARING SAME

Info

Publication number
PE20251270A1
PE20251270A1 PE2025000428A PE2025000428A PE20251270A1 PE 20251270 A1 PE20251270 A1 PE 20251270A1 PE 2025000428 A PE2025000428 A PE 2025000428A PE 2025000428 A PE2025000428 A PE 2025000428A PE 20251270 A1 PE20251270 A1 PE 20251270A1
Authority
PE
Peru
Prior art keywords
evogliptin
metformin
granules containing
release
rapid
Prior art date
Application number
PE2025000428A
Other languages
Spanish (es)
Inventor
Dong Han Won
Hwan-Ho Kim
Jeong Woong Seo
Ah Young Kim
Original Assignee
Dong A St Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A St Co Ltd filed Critical Dong A St Co Ltd
Publication of PE20251270A1 publication Critical patent/PE20251270A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a una formulacion compuesta que es una composicion compuesta oral que consiste en evogliptina, que es un agente de tratamiento de la diabetes y es un inhibidor de DPP-4, y metformina, que es un agente de tratamiento de la diabetes de biguanida, y que comprende granulos de liberacion rapida que contienen evogliptina que muestra liberacion rapida, y granulos de liberacion sostenida que contienen metformina que muestra liberacion sostenida; y un metodo para preparar la misma. La formulacion compuesta, se preparo en forma de un comprimido bicapa usando los granulos de liberacion rapida que contienen evogliptina y granulos que contienen metformina. Aunque el contenido de evogliptina usada como principio activo en la formulacion compuesta es solo una cantidad minima del 0,5 % en peso, el contenido es uniforme, se muestra una alta tasa de disolucion, y la metformina, que es el otro principio activo, se libera lentamente.It relates to a compound formulation which is an oral compound composition consisting of evogliptin, which is a diabetes treatment agent and is a DPP-4 inhibitor, and metformin, which is a biguanide diabetes treatment agent, and comprising rapid-release granules containing evogliptin showing rapid release, and sustained-release granules containing metformin showing sustained release; and a method for preparing the same. The compound formulation was prepared in the form of a bilayer tablet using the rapid-release granules containing evogliptin and granules containing metformin. Although the content of evogliptin used as an active ingredient in the compound formulation is only a minimum amount of 0.5% by weight, the content is uniform, a high dissolution rate is exhibited, and metformin, which is the other active ingredient, is released slowly.

PE2025000428A 2022-08-24 2022-08-24 COMPOUND ORAL FORMULATION COMPRISING EVOGLIPTIN AND METFORMIN, AND METHODS OF PREPARING SAME PE20251270A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2022/012670 WO2024043358A1 (en) 2022-08-24 2022-08-24 Oral composite formulation comprising evogliptin and metformin and method for preparing same

Publications (1)

Publication Number Publication Date
PE20251270A1 true PE20251270A1 (en) 2025-05-14

Family

ID=90013567

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2025000428A PE20251270A1 (en) 2022-08-24 2022-08-24 COMPOUND ORAL FORMULATION COMPRISING EVOGLIPTIN AND METFORMIN, AND METHODS OF PREPARING SAME

Country Status (6)

Country Link
CO (1) CO2025001893A2 (en)
CR (1) CR20250096A (en)
DO (1) DOP2025000039A (en)
MX (1) MX2025002056A (en)
PE (1) PE20251270A1 (en)
WO (1) WO2024043358A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020245801A1 (en) * 2019-03-25 2021-11-11 The George Institute for Global Health Low-dose triple combination formulation
US11684596B2 (en) * 2020-09-22 2023-06-27 Elite Pharmaceuticals Solution Inc. Antidiabetic pharmaceutical compositions and preparation method thereof

Also Published As

Publication number Publication date
DOP2025000039A (en) 2025-06-15
WO2024043358A1 (en) 2024-02-29
MX2025002056A (en) 2025-05-02
CR20250096A (en) 2025-06-27
CO2025001893A2 (en) 2025-05-19

Similar Documents

Publication Publication Date Title
JP2021066744A5 (en) Composition containing bupropion and dextromethorphan
WO2005009357A3 (en) Controlled release compositions
PE20070693A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN
ECSP11006707A (en) FORMULATION FOR DIRECT COMPRESSION AND PROCESS
ES2240033T3 (en) MARRIAGE TABLET THAT ALLOWS THE PROLONGED TRIMETAZIDINE RELEASE AFTER ITS ORAL ADMINISTRATION.
PE20061017A1 (en) PHARMACEUTICAL FORMULATION BY DIRECT COMPRESSION OF A DIPEPTIDIL-PEPTIDASE IV INHIBITOR AND PROCESS
EA200700049A1 (en) PREPARATIVE FORMS OF ORAL MEDICINAL FORMS OF MEMANTINE WITH MODIFIED SURVIVAL
HUP0000759A2 (en) Dosage forms containing R- and S-enantiomers in separate portions
AR061166A1 (en) PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF PHENYLPHERINE
ECSP099439A (en) COMPOSITION OF SUSTAINED RELEASE AND METHODS TO PRODUCE
AR077284A1 (en) SOLID PHARMACEUTICAL FIXED DOSAGE COMPOSITIONS INCLUDING IRBESARTAN AND AMLODIPINE, ITS PREPARATION AND THERAPEUTIC APPLICATION
CO2024002256A2 (en) 5-Hydroxytryptophan Gastroretentive Dosage Forms
PE20081464A1 (en) PHARMACEUTICAL COMPOSITION OF MODIFIED RELEASE OF A RELAXING MUSCLE AND AN NSAID
PE20251270A1 (en) COMPOUND ORAL FORMULATION COMPRISING EVOGLIPTIN AND METFORMIN, AND METHODS OF PREPARING SAME
CL2008001678A1 (en) Extended-release pharmaceutical dosage form in tablet form, consisting of anhydrous nevirapine, hypromellose, lactose monohydrate, and magnesium stearate; and its preparation procedure, useful for the treatment of HIV-1 infection.
AR046410A1 (en) PHARMACEUTICAL COMPOSITIONS FOR MODIFIED LIBERATION OF MODAFINILO
CL2025000483A1 (en) Compound oral formulation comprising evogliptin and metformin and method of preparation thereof
CU20070094A7 (en) SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE
PE20061245A1 (en) COMPOSITIONS FOR ORAL TRANSMUCOUS TRANSMISSION OF METFORMIN
RU2014146936A (en) Immediate Release Formulations
AR132497A1 (en) Combination of amorphous OBICETRAPIB and SGLT2 inhibitor
CN117440807A (en) Apixaban membrane products and their uses
PE20230105A1 (en) DOSAGE FORM PROVIDING SUPPORTED RELEASE OF TAPENTADOL PHOSPHORIC ACID SALT
TW201201800A (en) A pharmaceutical controlled release composition of losartan
Nishanth et al. Formulation Development and Evaluation of Bilayer Tablets of Telmisartan for Immediate Release and Metformin Hydrochloride for Sustained Release